Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reclast Registry for Hypocalcemia in Paget's Disease
NCT00668200Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2008
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in Paget's disease of bone, sponsored by Novartis. Primary endpoint: Percentage of Patients With Serum Calcium <2.07 mmol/L at 30 days. Started May 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Paget's disease of bone
Beyond the preview
Go deeper on NCT00668200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668200.